Proof of principle has been demonstrated in glioblastoma where ENO1, a passenger gene frequently homozygously deleted at 1p36, leads to a synthetic vulnerability, whereby inhibition its paralogue, ENO2, in ENO1‐deficient cells is cell lethal (Muller et al., 2012). The gene discussed is ENO1; the disease is glioblastoma.